Paper Details

  1. Home
  2. Paper Details

Durable effect of pyrotinib plus capecitabine in HER-2+ breast cancer patient undergoing peritoneal dialysis: A case report and literature review.

Author: JinXiangting, LiFanfan, YanMin

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This case study highlights the potential benefits of using a combination of pyrotinib and capecitabine in treating HER-2+ breast cancer in patients with end-stage renal disease. The combination therapy was effective in reducing tumor size, with a significant reduction after one month of pyrotinib alone and partial relief after two months of the combined treatment. The main side effects were grade II hand foot syndrome and grade II diarrhea. This suggests that this treatment approach could be a viable option for patients with HER-2+ breast cancer and end-stage renal disease.
Paper Details　
Original Abstract of the Article :
For patients with end-stage renal disease (ESRD), peritoneal dialysis (PD) and hemodialysis (HD) are important renal replacement treatments. Patients on dialysis usually have a high incidence rate of malignant tumors. In 2020, breast cancer has become the malignant tumor with the highest incidence r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780055/

データ提供：米国国立医学図書館（NLM）

A Beacon of Hope in the Desert of HER-2+ Breast Cancer

The world of cancer treatment is a vast and challenging desert, with patients facing a relentless battle against disease. This case report presents a glimmer of hope for patients with [HER-2+ breast cancer], a particularly aggressive form of the disease. This case highlights the potential benefits of a combination therapy involving [pyrotinib] and [capecitabine] in a patient undergoing [peritoneal dialysis] for [end-stage renal disease]. The patient experienced significant tumor reduction after treatment, demonstrating the effectiveness of this combination approach. This case report adds valuable insights into the treatment of [HER-2+ breast cancer] in a challenging clinical context.

Hope in the Desert: A Promising Combination Therapy

The results of this case report are promising, suggesting that this combination therapy may be a viable option for patients with [HER-2+ breast cancer] who are also undergoing [peritoneal dialysis]. The significant tumor reduction observed in this patient offers hope for future treatments, and the use of [pyrotinib] and [capecitabine] in combination may offer a more effective approach than using these drugs individually.

Navigating the Desert of Cancer Treatment: A Journey of Resilience

For patients facing [HER-2+ breast cancer], navigating the desert of treatment can be a daunting experience. This case report highlights the importance of ongoing research and the potential for innovative therapies to provide hope and relief. It also underscores the need for individualized care, taking into account the specific needs and challenges of each patient.

Dr.Camel's Conclusion

This case report is like finding a hidden spring in the desert, offering a new source of hope for patients with [HER-2+ breast cancer]. It demonstrates the power of collaboration between medical professionals and the potential for groundbreaking therapies to improve patient outcomes. The journey through cancer treatment can be long and arduous, but the search for new and effective treatments continues, offering a beacon of hope to those who are battling this disease.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-01-03
Further Info :

Pubmed ID

36568221

DOI: Digital Object Identifier

PMC9780055

Related Literature

Article Analysis
・Side Effects of capecitabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.